Key Laboratory of Radiopharmaceuticals, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing, China.
J Nucl Med. 2011 Jun;52(6):978-85. doi: 10.2967/jnumed.110.085167. Epub 2011 May 13.
Poly(vinylbenzyl-O-β-D-galactopyranosyl-D-gluconamide) (PVLA) can be specifically internalized by hepatocytes via the asialoglycoprotein receptor. In this study, we synthesized and characterized galactose-carrying copolymers with hydrazinonicotinamide chains as bifunctional groups to radiolabel PVLA with (99m)Tc for SPECT targeting specific hepatocytes.
Poly(N-p-vinylbenzyl-[O-β-D-galactopyranosyl-(1→4)-D-gluconamide]-co-N-p-vinylbenzyl-6-[2-(4-dimethylamino)benzaldehydehydrazono]nicotinate) (P(VLA-co-VNI)) was first prepared via copolymerization of N-p-vinylbenzyl-O-β-D-galactopyranosyl-D-gluconamide with 5% (mol) of N-p-vinylbenzyl-(4-dimethylaminobenzaldehyde hydrazono)nicotinamide. The copolymer was labeled with (99m)Tc using tricine as a coligand. Then (99m)TcP(VLA-co-VNI)(2) was evaluated by in vivo metabolic stability and biodistribution in normal mice. SPECT was performed in normal New Zealand White rabbits and rabbits with liver cancer.
(99m)TcP(VLA-co-VNI)(2) was prepared in high labeling yield (>95%) and radiochemical purity (>99%), with good stability. The results of biodistribution in mice demonstrated that the liver uptake was 125.33 ± 10.99 percentage injected dose per gram at 10 min after injection and could be blocked significantly by preinjecting free neogalactosylalbumin or P(VLA-co-VNI). SPECT images with high quality were obtained at 15, 30, 60, and 120 min after injection of the radiotracer. Significant radioactivity defect was observed in the liver cancer model.
The bifunctional coupling agent hydrazinonicotinamide was introduced to PVLA via copolymerization and labeled with (99m)Tc. The promising biologic properties of (99m)TcP(VLA-co-VNI)(2) afford potential applications for the assessment of hepatocyte function in the future.
聚(苯乙烯基-O-β-D-半乳糖基-D-葡糖酰胺)(PVLA)可通过去唾液酸糖蛋白受体被肝细胞特异性内化。在这项研究中,我们合成并表征了带有酰肼基吡啶酰胺链作为双功能基团的携带半乳糖的共聚物,以便用(99m)Tc 对 PVLA 进行放射性标记,用于 SPECT 靶向特定的肝细胞。
首先通过 N-对乙烯基苄基-O-β-D-半乳糖基-D-葡糖酰胺与 5%(摩尔)的 N-对乙烯基苄基-(4-二甲基氨基苯甲醛酰肼基)吡啶酰胺共聚合成聚(N-对乙烯基苄基-O-β-D-半乳糖基-(1→4)-D-葡糖酰胺)-共-N-对乙烯基苄基-6-[2-(4-二甲基氨基)苯甲醛酰肼基]吡啶酰胺(P(VLA-co-VNI))。使用三乙胺作为共配体,用(99m)Tc 对共聚物进行标记。然后在正常小鼠中评估(99m)Tc[P(VLA-co-VNI)](三乙胺)(2)的体内代谢稳定性和生物分布。在正常新西兰白兔和肝癌兔中进行 SPECT。
(99m)Tc[P(VLA-co-VNI)](三乙胺)(2)的标记产率(>95%)和放射化学纯度(>99%)均较高,稳定性良好。在小鼠的生物分布研究中,注射后 10 分钟时,肝脏摄取率为每克 125.33±10.99%注入剂量,并且可以通过预先注射游离新半乳糖白蛋白或 P(VLA-co-VNI)显著阻断。在注射示踪剂后 15、30、60 和 120 分钟获得了高质量的 SPECT 图像。在肝癌模型中观察到明显的放射性缺陷。
通过共聚反应将双功能偶联剂酰肼基吡啶酰胺引入 PVLA,并对其进行(99m)Tc 标记。(99m)Tc[P(VLA-co-VNI)](三乙胺)(2)具有良好的生物学特性,为将来评估肝细胞功能提供了潜在的应用。